This study aimed to investigate the effect of isotretinoin and thalidomide on c-MYC gene expression and other proteins associated with cancer in a human hepatic cell line, in order to assess their use alone or in combination with other HCC-specific drugs, such as sorafenib, as a promising option for modulation of the expression of oncogenes and tumor suppressor genes for the treatment of HCC. The gene discussed is MYC; the disease is hepatocellular carcinoma.